|Mr. David A. Cory M.B.A., R.Ph., R.Ph, MBA||Bus. Founder, Pres, CEO & Director||1M||N/A||1964|
|Dr. Jeffrey S. Glenn||Founder, Scientific Advisor & Independent Director||57.5k||N/A||1963|
|Mr. Sriram Ryali M.B.A.||Chief Financial Officer||567.12k||N/A||1981|
|Dr. Evan Loh||CEO of Paratek Pharmaceuticals & Director||60k||N/A||1959|
|Mr. Eldon C. Mayer III, M.B.A.||Exec. VP & Chief Commercial Officer||657.15k||N/A||1961|
|Dr. Ingrid C. Choong||Sr. VP of Clinical Devel.||N/A||N/A||N/A|
|Mr. James P. Shaffer M.B.A., MBA||Chief Bus. Officer||N/A||N/A||1967|
|Dr. Stephana E. Patton||Consultant||N/A||N/A||1971|
|Mr. Rich Franco M.B.A.||Sr. VP & Progeria Program Lead||N/A||N/A||N/A|
|Dr. Colin Hislop||Sr. VP of Clinical & Devel. Operations||N/A||N/A||1958|
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. The company was founded in 2008 and is headquartered in Palo Alto, California.
Eiger BioPharmaceuticals, Inc.’s ISS Governance QualityScore as of April 30, 2021 is 7. The pillar scores are Audit: 2; Board: 5; Shareholder Rights: 8; Compensation: 9.